Evidence map›Paper›PMID 41003947›Full record

ArticleEJNMMI radiopharmacy and chemistry2025

[

Romy Cools, Valeria Narykina, Koen Vermeulen, Sanket J Mishra, Brian S J Blagg, Marleen Derweduwe, Frederik De Smet, Aaron Ziani-Zeryouh, Matteo Riva, An Coosemans and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. FirstResearch square · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Romy Cools *Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000, Louvain, Belgium.
Valeria Narykina *Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000, Louvain, Belgium.
Koen VermeulenNURA, Belgian Nuclear Research Centre (SCK CEN), 2400, Mol, Belgium.
Sanket J MishraWarren Family Research Center for Drug Discovery and Development and Department of Chemistry & Biochemistry, University of Notre Dame, 305 McCourtney Hall, Notre Dame, IN, 46556, USA.
Brian S J BlaggWarren Family Research Center for Drug Discovery and Development and Department of Chemistry & Biochemistry, University of Notre Dame, 305 McCourtney Hall, Notre Dame, IN, 46556, USA.
Marleen DerweduweThe Laboratory for Precision Cancer Medicine, Translational Cell and Tissue Research Unit, Department of Imaging & Pathology, KU Leuven, 3000, Louvain, Belgium.
Frederik De SmetThe Laboratory for Precision Cancer Medicine, Translational Cell and Tissue Research Unit, Department of Imaging & Pathology, KU Leuven, 3000, Louvain, Belgium.
Aaron Ziani-ZeryouhLaboratory for Tumour Immunology and Immunotherapy, Department Oncology, 3000, Leuven, KU Leuven, Belgium.
Matteo RivaLaboratory for Tumour Immunology and Immunotherapy, Department Oncology, 3000, Leuven, KU Leuven, Belgium.
An CoosemansLaboratory for Tumour Immunology and Immunotherapy, Department Oncology, 3000, Leuven, KU Leuven, Belgium.
Frederic RousseauSwitch Laboratory, VIB Center for Brain and Disease Research, Herestraat 49, 3000, Louvain, Belgium.
Joost SchymkowitzSwitch Laboratory, VIB Center for Brain and Disease Research, Herestraat 49, 3000, Louvain, Belgium.
Guy BormansLaboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000, Louvain, Belgium. guy.bormans@kuleuven.be.ORCID http://orcid.org/0000-0002-0335-7190

Funding

Development of Hsp90 Isoform- Selective Inhibitors as a Novel Opioid Dose-Reduction TherapyR01DA052340 · NIDA · UNIVERSITY OF ARIZONA · PI STREICHER, JOHN MICHAEL · 2021 to 2025
$3.3M
Engineering the Next Generation of Safer Hsp90 InhibitorsR01CA270147 · NCI · UNIVERSITY OF NOTRE DAME · PI Brian S J Blagg, Mark Steven Cohen · 2023 to 2026
$1.8M
FWO G0A6222NFWO infrastructure AKUL15-30/G0H1216NNCI NIH HHS R01 CA270147NIDA NIH HHS R01 DA052340NIH HHS CA270147NIH HHS DA052340Onderzoeksraad, KU Leuven C24E/19/070VIB C0401
6 · The paper itself

Abstract

backgroundHsp90 is a molecular chaperone that is often overexpressed across multiple cancer types and has a potential value as a prognostic marker as well as a therapeutic target. Given the high interest in Hsp90 therapies, positron emission tomography or PET imaging of Hsp90 can be a valuable tool for patient selection. The limitations of the previously developed Hsp90 tracers prompted us to evaluate the recently developed brain-permeable [

resultsIn vitro [

conclusion[

Indexed as

CancerDiagnosticsGlioblastomaHeat shock proteins

Identifiers

PMID41003947
PMCPMC12474755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.